Company Overview of Cerecor Inc.
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406...
400 East Pratt Street
Baltimore, MD 21202
Founded in 2011
Key Executives for Cerecor Inc.
Co-Founder,Chief Executive Officer, President and Director
Founder, Vice Chairman and Member of Nominating & Corporate Governance Committee
Founder and Chairman of Scientific Advisory Board
Founder and Member of Scientific Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.
Cerecor Inc. Key Developments
Cerecor Eyes Acquisitions
Jun 12 15
Cerecor, Inc. is looking for acquisitions. The company has filed an IPO in the amount of $31.63 million. They intend to use the net proceeds from this offering, together with their existing cash and cash equivalents, to fund the costs of Phase 2 clinical development of CERC-301 and CERC-501, preclinical research for CERC-406, research and development to build their COMTi platform and potential in licensing or other acquisitions and for working capital and general corporate purposes.
Cerecor, Inc. Auditor Raises 'Going Concern' Doubt
Jun 12 15
Cerecor, Inc. filed its Annual on Jun 12, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Cerecor Inc. Announces Board Changes
May 29 15
Cerecor Inc. announced that it has appointed Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs. Dr. Marcus has more than 20 years of experience in the development of neuroscience drugs at both Spinifex and Bristol-Myers Squibb (BMS). In addition, the company has appointed Uli Hacksell, PhD, as Chairman of the Board of Directors. Dr. Hacksell was most recently CEO of ACADIA Pharmaceuticals Inc. Dr. Hacksell is replacing Sol Barer, PhD, who stepped down as the Chairman and as a member of the company’s board of directors in April 2015. Dr. Marcus was most recently the Chief Medical Officer at Spinifex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|